6-K
Foreign Interim / Material
Cordyceps Sunshine Biotech Holdings Co., Ltd. RAJAF
0001213900-23-085555
- Filed
- Nov 13, 2023 12:00 AM ET
- Period of report
- —
On SEC.gov
Financials in this filing
| Metric | Period | Value |
|---|---|---|
| Shares Diluted | Q3 2023 · Sep 30, 2023 | 111.12M sh |
| Shares Diluted | Q3 2023 · Sep 30, 2022 | 100M sh |
| Capex | Q3 2023 · Sep 30, 2023 | $1.54M |
| Operating Cash Flow | Q3 2023 · Sep 30, 2023 | $1.59M |
| Operating Cash Flow | Q3 2023 · Sep 30, 2022 | −$210.56K |
| Short Term Debt | Q3 2023 · Sep 30, 2023 | $99.06K |
| Cash And Equivalents | Q3 2023 · Sep 30, 2023 | $16.91K |
| Cash And Equivalents | Q3 2023 · Dec 31, 2022 | $16.1K |
| Stockholders Equity | Q3 2023 · Sep 30, 2023 | −$182.94K |
| Stockholders Equity | Q3 2023 · Dec 31, 2022 | −$951.33K |
| Stockholders Equity | Q3 2023 · Sep 30, 2022 | $117.09K |
| Stockholders Equity | Q3 2023 · Dec 31, 2021 | $466.2K |
| Current Liabilities | Q3 2023 · Sep 30, 2023 | $1.47M |
| Current Liabilities | Q3 2023 · Dec 31, 2022 | $2.52M |
| Total Liabilities | Q3 2023 · Sep 30, 2023 | $1.98M |
| Total Liabilities | Q3 2023 · Dec 31, 2022 | $3.06M |
| Current Assets | Q3 2023 · Sep 30, 2023 | $52.14K |
| Current Assets | Q3 2023 · Dec 31, 2022 | $501.55K |
| Total Assets | Q3 2023 · Sep 30, 2023 | $1.8M |
| Total Assets | Q3 2023 · Dec 31, 2022 | $2.1M |
| Eps Diluted | Q3 2023 · Sep 30, 2023 | $0.00 |
| Eps Diluted | Q3 2023 · Sep 30, 2022 | −$0.01 |
| Eps Basic | Q3 2023 · Sep 30, 2023 | $0.00 |
| Eps Basic | Q3 2023 · Sep 30, 2022 | −$0.01 |
| Sga Expense | Q3 2023 · Sep 30, 2023 | $188.4K |
| Sga Expense | Q3 2023 · Sep 30, 2022 | $254.91K |
| Net Income | Q3 2023 · Sep 30, 2023 | −$149.56K |
| Net Income | Q3 2023 · Sep 30, 2022 | −$643.05K |
| Operating Income | Q3 2023 · Sep 30, 2023 | $107.39K |
| Operating Income | Q3 2023 · Sep 30, 2022 | −$378.22K |
| Gross Profit | Q3 2023 · Sep 30, 2023 | $481.73K |
| Cost Of Revenue | Q3 2023 · Sep 30, 2023 | $85.3K |
| Revenue | Q3 2023 · Sep 30, 2023 | $567.03K |